Pharma Watch

Leading Pharma Leading Pharma

Challenged Pharma Challenged Pharma

EpicentRx Receives FDA Clearance of IND for Adenovirus Program AIM-001

EpicentRx Receives FDA Clearance of IND for Adenovirus Program AIM-001

EpicentRx announced that the U.S. FDA has cleared the investigational new drug (IND) application for AIM-001, an oncolytic adenovirus that is enhanced with a TGF-β (beta) trap transgene. EpicentRx plans to begin clinical trials with AIM-001 this year. Cancer cells...

subscribe

subscribe
University at Buffalo
subscribe

Pin It on Pinterest